Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study
Authors' conclusion
SGLT2 inhibitors versus DPP4 inhibitors were associated with a lower risk of incident dementia in patients with T2D and comorbid mental disorders. Further randomized controlled trials are required to confirm our findings.
Study context
- Population
- Patients with T2D and comorbid mental disorders, nationwide healthcare data of South Korea, 2010–2022
- Exposure
- SGLT2 inhibitors vs DPP4 inhibitors
- Outcome
- Incident dementia
- Follow-up
- 4.8-year median
Methodological detailsactive comparator, new-user (initiators), propensity score fine stratification weighting, nationwide
- Active comparator
- New-user (initiators)
- Propensity score fine stratification weighting
- Nationwide
Main finding
As reported in the abstract
SGLT2 inhibitors vs DPP4 inhibitorsHazard ratio (95 % CI)
12 % lower risk
0.88(0.84–0.92)
SGLT2 inhibitors vs DPP4 inhibitorsRD, per 1000 person-years (95 % CI)
Incident dementia
−1.55(−2.13 to −0.97)
Observational data: associations, not effects.
Further findings
Subgroups: age, sex, individual component, severe mental disorders, insulin, CVD history, hypertension history
- Results consistent across strata
Original publication
Sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase IV inhibitors and risk of dementia among patients with type 2 diabetes and comorbid mental disorders: A population-based cohort study. Diabetes Metab. Published 28 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →